CYTOSPIRE
LIVE

Serial Number

79455621

Owner

Cytospire Therapeutics Limited

Filing Date

Jun 26, 2026

Add to watchlist:

No watchlists yet
View on USPTO

CYTOSPIRE Trademark

Serial Number: 79455621

CYTOSPIRE is a trademark filed by Cytospire Therapeutics Limited on June 26, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Cytospire Therapeutics Limited

3rd Floor 1 Ashley Road

Entity Type: 98

Trademark Details

Filing Date

June 26, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the prevention and treatment of cancer and tumours; pharmaceutical preparations for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for medical purposes; biological preparations for the prevention and treatment of cancer and tumours; biological preparations for use in the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for use in the prevention and treatment of cancer and tumours; biopharmaceuticals for the treatment of cancer; antibodies; diagnostic reagents for medical use.

Scientific and technological services; scientific research; pharmaceutical research and development services; medical research services; drug development services; laboratory analysis; laboratory research; laboratory testing; testing of pharmaceuticals; pharmaceutical research and development services in the field of oncology and immunotherapy; pharmaceutical research and development of pharmaceuticals and drugs for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; medical research services in the field of oncology and immunotherapy; medical research services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; drug development services in the field of oncology and immunotherapy; drug development services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; laboratory research and testing of pharmaceuticals in the field of oncology and immunotherapy; laboratory research and testing of pharmaceuticals for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; research and development services in the field of antibodies; research and development in the field of biotechnology; development of antibodies; development of antibodies for use in the field of oncology and immunotherapy; information, consultancy and advice in relation to the aforesaid services.

Filing History

APPLICATION FILING RECEIPT MAILED
Aug 13, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 13, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 6, 2026 REPR